Neoadjuvant therapy with cisplatin in BRCA1-positive breast cancer patients

Neoadjuvant therapy with cisplatin in BRCA1-positive breast cancer patients

Bibliographic Details
Main Authors:	Byrski T, Gronwald J, Huzarski T, Dent RA, Zuziak D, Wiśniowski R, Marczyk E, Blecharz P, Szurek O, Cybulski C, Dębniak T, Górski B, Lubiński J, Narod S
Format:	Article
Language:	English
Published:	BMC 2011-06-01
Series:	Hereditary Cancer in Clinical Practice
Online Access:	http://www.hccpjournal.com/content/9/S2/A4

Similar Items

Neoadjuvant chemotherapy with Cisplatin in BRCA1 mutation carriers – results of treatment
by: Byrski T, et al.
Published: (2012-04-01)

Why choose the treatment with cisplatin for BRCA1 breast cancers patients?
by: Byrski T, et al.
Published: (2012-01-01)

Cisplatin in breast cancer treatment in BRCA1 carriers
by: Gronwald Jacek, et al.
Published: (2012-12-01)

CHEK2 mutations as markers for high risk of breast cancer
by: Cybulski Cezary, et al.
Published: (2012-04-01)

A Lowering of Breast and Ovarian Cancer Risk in Women with a BRCA1 Mutation by Selenium Supplementation of Diet
by: Huzarski Tomasz, et al.
Published: (2006-01-01)

The risk of breast cancer in women with a CHEK2 mutation
by: Cybulski Cezary, et al.
Published: (2012-01-01)

Impact of BRCA1 mutation on survival after early onset breast cancer
by: Huzarski T, et al.
Published: (2012-12-01)

Selenium and the risk of cancer in BRCA1 carriers
by: Lubinski J, et al.
Published: (2011-06-01)

Prospective observation of breast/ovarian cancer risk in BRCA1 carriers depending on serum selenium level optimized with diet
by: Lubiński J, et al.
Published: (2012-01-01)

Folic acid and cancer risk in BRCA1 carriers
by: Durda Katarzyna, et al.
Published: (2012-04-01)

Coverage of the Genetic Background of Breast Cancer in the Polish Population
by: Serrano-Fernández Pablo, et al.
Published: (2006-11-01)

Serum concentration of selected macro- and microelements and their correlation with the risk of breast and ovarian cancer among BRCA1 mutation carriers
by: Muszyńska Magdalena, et al.
Published: (2012-04-01)

Frequency of BRCA1 and BRCA2 causative founder variants in ovarian cancer patients in South-East Poland
by: Tomasz Kluz, et al.
Published: (2018-02-01)

BRCA1 and BRCA2 mutations in ovarian cancer patients from Belarus: update
by: Alena Savanevich, et al.
Published: (2021-01-01)

Selenium and genotypes as marker of risk in BRCA1 mutation carriers
by: Jaworska K, et al.
Published: (2012-01-01)

Ovarian cancer risk in Polish <it>BRCA1 </it>mutation carriers is not associated with the prohibitin 3' untranslated region polymorphism
by: Benner Axel, et al.
Published: (2008-04-01)

Serum concentration of iron as predictor of cancer risk among BRCA1 mutation carriers
by: Sukiennicki Grzegorz, et al.
Published: (2012-04-01)

Recurrent Mutations in <i>BRCA1</i>,<i> BRCA2</i>,<i> RAD51C</i>,<i> PALB2</i> and <i>CHEK2</i> in Polish Patients with Ovarian Cancer
by: Alicja Łukomska, et al.
Published: (2021-02-01)

Identification of patients at high risk of negative psychological consequences associated with BRCA1 mutation
by: Ertmański S, et al.
Published: (2012-01-01)

Blood Arsenic Levels as a Marker of Breast Cancer Risk among <i>BRCA1</i> Carriers
by: Wojciech Marciniak, et al.
Published: (2021-07-01)

Vitamins A, E and D and cancer risk in BRCA1 carriers
by: Kąklewski K, et al.
Published: (2012-04-01)

<it>BRCA1 </it>testing
by: Górski Bohdan, et al.
Published: (2008-06-01)

Neoadjuvant therapy of BRCA1-driven ovarian cancer by combination of cisplatin, mitomycin C and doxorubicin
by: Tatiana V. Gorodnova, et al.
Published: (2021-02-01)

Prevalence of Recurrent Mutations Predisposing to Breast Cancer in Early-Onset Breast Cancer Patients from Poland
by: Emilia Rogoża-Janiszewska, et al.
Published: (2020-08-01)

Iron and breast cancer risk
by: Sukiennicki Grzegorz, et al.
Published: (2012-12-01)

Hereditary breast and ovarian cancer
by: Gronwald Jacek, et al.
Published: (2008-06-01)

Predisposición genética para el cáncer de mama: genes BRCA1 y BRCA2 Genetic predisposition for breast cancer: BRCA1 and BRCA2 genes
by: Steven A Narod, et al.
Published: (2011-10-01)

Genetic predisposition to male breast cancer in Poland
by: Marek Szwiec, et al.
Published: (2021-08-01)

Neoadjuvant niraparib in patients with HER2-negative, BRCA-mutated resectable breast cancer
by: L.M. Spring, et al.
Published: (2021-04-01)

Screening for BRCA1 and BRCA2 mutations in breast cancer patients from mexico: the public health perspective Tamizaje de BRCA1 y BRCA2 en pacientes con cáncerde mama en méxico: perspectiva de la salud pública
by: Steven A Narod
Published: (2009-01-01)

Population Screening of CHEK2 Mutations in Poland
by: Cybulski Cezary, et al.
Published: (2006-01-01)

Population Screening for Cancer Family Syndromes in the West Pomeranian Region of Poland
by: Gronwald Jacek, et al.
Published: (2006-01-01)

Serum Selenium Level Predicts 10-Year Survival after Breast Cancer
by: Marek Szwiec, et al.
Published: (2021-03-01)

Platinum-Based Neoadjuvant Chemotherapy for Breast Cancer With BRCA Mutations: A Meta-Analysis
by: Chang-Jun Wang, et al.
Published: (2020-11-01)

Clinical Genetic Services for Familial Breast Cancer in Poland
by: J. Gronwald, et al.
Published: (1999-01-01)

Prevalence of <it>BRCA1 </it>and <it>BRCA2 </it>mutations in unselected breast cancer patients from Greece
by: Koumpis Chrissovaladis, et al.
Published: (2011-11-01)

Large genomic rearrangements in BRCA1 and BRCA2 genes in breast and ovarian cancer families in Poland
by: Bielecka Helena, et al.
Published: (2012-01-01)

Large genomic rearrangements in BRCA1 and BRCA2 genes in breast and ovarian cancer families in Poland
by: Bielecka Helena, et al.
Published: (2012-04-01)

BRCA1 mRNA expression levels as an predictor of response to neoadjuvant chemotherapy in breast cancer
by: M. M. Tsyganov, et al.
Published: (2018-05-01)

Gene Expression Profiling in Hereditary, BRCA1-linked Breast Cancer: Preliminary Report
by: Dudaladava Volha, et al.
Published: (2006-01-01)